Table of Content

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Precision Medicine
5.2.1. Evolution of Precision Medicine
5.3. Oncology Precision Medicine
5.3.1. Oncology Precision Medicine over Traditional Cancer Medicine
5.3.2. Steps Involved in Developing Oncology Precision Medicine
5.3.3. Advantages Associated with Oncology Precision Medicine
5.3.3.1. Benefits to the Patients
5.3.3.2. Benefits to the Healthcare Providers
5.3.3.3. Benefits to the Cancer Researchers
5.3.4. Challenges Associated with Oncology Precision Medicines
5.3.5. Future Perspectives

6. ONCOLOGY PRECISION MEDICINE: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Oncology Precision Medicine: Commercialized and Clinical Stage Drugs Market Landscape
6.2.1. Analysis by Stage of Development
6.2.2. Analysis by Approval Body
6.2.3. Analysis by Approval Region
6.2.4. Analysis by Drug Designation
6.2.5. Analysis by Type of Molecule
6.2.6. Analysis by Drug Class
6.2.7. Analysis by Route of Administration
6.2.8. Analysis by Dosage Regimen
6.2.9. Analysis by Patient Population
6.2.10. Analysis by Type of Cancer Targeted
6.2.11. Analysis by Stage of Development and Type of Cancer Targeted
6.3. Oncology Precision Medicine: Preclinical and Discovery Stage Drugs Market Landscape
6.3.1. Analysis by Stage of Development
6.3.2. Analysis by Type of Molecule
6.3.3. Analysis by Drug Class
6.3.4. Analysis by Type of Cancer Targeted
6.4. Oncology Precision Medicine: Developer Landscape
6.4.1. Analysis by Year of Establishment
6.4.2. Analysis by Company Size
6.4.3. Analysis by Location of Headquarters (Region)
6.4.4. Analysis by Location of Headquarters (Country)
6.4.5. Analysis by Company Size and Location of Headquarters (Region)
6.4.6. Most Active Players: Analysis by Number of Oncology Precision Medicines

7. DETAILED COMPANY PROFILES
7.1. Chapter Overview
7.2. AstraZeneca
7.2.1. Company Overview
7.2.2. Financial Information
7.2.3. Oncology Precision Medicine Portfolio
7.2.4. Recent Developments and Future Outlook
7.3. Genentech
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Oncology Precision Medicine Portfolio
7.3.4. Recent Developments and Future Outlook
7.4. Jiangsu Hengrui Pharmaceuticals
7.4.1. Company Overview
7.4.2. Oncology Precision Medicine Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. Johnson & Johnson Innovative Medicine
7.5.1. Company Overview
7.5.2. Financial Information
7.5.3. Oncology Precision Medicine Portfolio
7.5.4. Recent Developments and Future Outlook
7.6. Novartis
7.6.1. Company Overview
7.6.2. Financial Information
7.6.3. Oncology Precision Medicine Portfolio
7.6.4. Recent Developments and Future Outlook
7.7. Pfizer
7.7.1. Company Overview
7.7.2. Financial Information
7.7.3. Oncology Precision Medicine Portfolio
7.7.4. Recent Developments and Future Outlook
7.8. SpringWorks Therapeutics
7.8.1. Company Overview
7.8.2. Oncology Precision Medicine Portfolio
7.8.3. Recent Developments and Future Outlook

8. SHORT COMPANY PROFILES
8.1. Chapter Overview
8.2. AbbVie
8.3. Anticancer Bioscience
8.4. Astellas Pharma
8.5. Bayer
8.6. Blueprint Medicines
8.7. Bristol Myers Squibb
8.8. Eli Lilly
8.9. Erasca
8.10. GlaxoSmithKline
8.11. Hutchmed
8.12. IDEAYA Biosciences
8.13. Merck
8.14. Repare Therapeutics
8.15. Roche
8.16. Seagen
8.17. Takeda Pharmaceutical
8.18. VERAXA Biotech
8.19. VRise Therapeutics

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Oncology Precision Medicine: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Drug Involved
9.3.6. Analysis by Type of Cancer Targeted
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Analysis by Geography
9.3.8.1. Local and International Agreements
9.3.8.2. Intracontinental and Intercontinental Agreements

10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Oncology Precision Medicine: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
10.3.3. Analysis by Trial Phase
10.3.4. Analysis of Number of Patients Enrolled by Trial Phase
10.3.5. Analysis by Trial Registration Year and Trial Phase
10.3.6. Analysis by Trial Status
10.3.7. Analysis by Trial Registration Year and Trial Status
10.3.8. Analysis by Target Patient Population
10.3.9. Analysis by Patient Gender
10.3.10. Analysis by Type of Cancer Targeted
10.3.11. Analysis by Type of Sponsor / Collaborator
10.3.12. Analysis by Study Design
10.3.12.1. Analysis by Type of Trial Masking
10.3.12.2. Analysis by Type of Intervention Model
10.3.12.3. Analysis by Type of Intervention
10.3.12.4. Analysis by Trial Purpose
10.3.13. Most Active Sponsors / Collaborators: Analysis by Number of Clinical Trials
10.3.13.1. Analysis by Leading Industry Players
10.3.13.2. Analysis by Leading Non-Industry Players
10.3.14. Word Cloud Analysis: Emerging Focus Areas
10.3.15. Analysis by Geography
10.3.15.1. Analysis of Clinical Trials by Geography
10.3.15.2. Analysis of Clinical Trials by Geography and Trial Status
10.3.15.3. Analysis of Patients Enrolled by Geography and Trial Status
11. CASE STUDY: ONCOLOGY PRECISION MEDICINE ASSAY KITS
11.1. Chapter Overview
11.2. Oncology Precision Medicine: Assay Kits
11.2.1. Analysis by Stage of Development
11.2.2. Analysis by Regulatory Certification / Compliance
11.2.3. Analysis by Regional Availability
11.2.4. Analysis by Type of Test
11.2.5. Analysis by Type of Sample Used
11.2.6. Analysis by Principle of Biomarker Detection
11.2.7. Analysis by Turnaround Time
11.2.8. Analysis by Type of Cancer Targeted
11.2.9. Analysis by Turnaround Time and Type of Cancer Targeted
11.2.10. Analysis by End-user
11.2.11. Analysis by Regional Availability and End-user
11.2.12. Analysis by Type of Cancer Targeted and End-user
11.3. Oncology Precision Medicine Assay Kits: Developer Landscape
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Location of Headquarters (Region)
11.3.4. Analysis by Location of Headquarters (Country)
11.3.5. Analysis by Company Size and Location of Headquarters (Region)
11.3.6. Analysis by Business Model
11.3.7. Most Active Players: Analysis by Number of Oncology Precision Medicine Assay Kits
12. CASE STUDY: TECHNOLOGIES USED IN PRECISION MEDICINE
12.1. Chapter Overview
12.2. Technologies Used in Precision Medicine
12.2.1. Next Generation Sequencing in Precision Medicine
12.2.2. Nanotechnology in Precision Medicine
12.2.3. Molecular Imaging Technologies in Precision Medicine
12.2.4. Omics Technologies in Precision Medicine
12.2.5. Artificial Intelligence (AI) in Precision Medicine
12.3. Conclusion

13. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
13.1. Chapter Overview
13.2. Market Drivers
13.3. Market Restraints
13.4. Market Opportunities
13.5. Market Challenges
13.6. Conclusion

14. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET
14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Global Oncology Precision Medicine Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
14.4. Scenario Analysis
14.4.1 Conservative Scenario
14.4.2. Optimistic Scenario
14.5. Key Market Segmentations

15. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF CANCER TARGETED
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035
15.3.1. Bladder Cancer: Forecasted Estimates (2023-2035)
15.3.2. Blood / Hematologic Cancer: Forecasted Estimates (2023-2035)
15.3.3. Breast Cancer: Forecasted Estimates (2023-2035)
15.3.4. Cervical Cancer: Forecasted Estimates (2023-2035)
15.3.5. Gastrointestinal Cancer: Forecasted Estimates (2023-2035)
15.3.6. Head and Neck Squamous Cell Cancer: Forecasted Estimates (2023-2035)
15.3.7. Lung Cancer: Forecasted Estimates (2023-2035)
15.3.8. Skin Cancer: Forecasted Estimates (2023-2035)
15.3.9. Other Cancers: Forecasted Estimates (2023-2035)
15.4. Data Triangulation and Validation

16. ONCOLOGY PRECISION MEDICINE MARKET, BY ROUTE OF ADMINISTRATION
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035
16.3.1. Oral: Forecasted Estimates (2023-2035)
16.3.2. Intravenous: Forecasted Estimates (2023-2035)
16.3.3. Others: Forecasted Estimates (2023-2035)
16.4. Data Triangulation and Validation

17. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF MOLECULE
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035
17.3.1. Small Molecules: Forecasted Estimates (2023-2035)
17.3.2. Biologics: Forecasted Estimates (2023-2035)
17.4. Data Triangulation and Validation

18. ONCOLOGY PRECISION MEDICINE MARKET, BY DRUG CLASS
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035
18.3.1. Kinase Inhibitors: Forecasted Estimates (2023-2035)
18.3.2. Enzyme Inhibitors: Forecasted Estimates (2023-2035)
18.3.3. Immune Checkpoint Inhibitors: Forecasted Estimates (2023-2035)
18.3.4. Others: Forecasted Estimates (2023-2035)
18.4. Data Triangulation and Validation

19. ONCOLOGY PRECISION MEDICINE MARKET, BY KEY GEOGRAPHICAL REGIONS
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035
19.3.1. North America: Forecasted Estimates (2023-2035)
19.3.1.1. US: Forecasted Estimates (2023-2035)
19.3.1.2. Canada: Forecasted Estimates (2023-2035)
19.3.2. Europe: Forecasted Estimates (2023-2035)
19.3.2.1. France: Forecasted Estimates (2023-2035)
19.3.2.2. Germany: Forecasted Estimates (2023-2035)
19.3.2.3. Italy: Forecasted Estimates (2023-2035)
19.3.2.4. Spain: Forecasted Estimates (2023-2035)
19.3.2.5. UK: Forecasted Estimates (2023-2035)
19.3.3. Asia: Forecasted Estimates (2023-2035)
19.3.3.1. China: Forecasted Estimates (2023-2035)
19.3.3.2. Japan: Forecasted Estimates (2023-2035)
19.3.3.3. Korea: Forecasted Estimates (2023-2035)
19.3.3.4. India: Forecasted Estimates (2023-2035)
19.3.4. Middle East and North Africa: Forecasted Estimates (2023-2035)
19.3.4.1. UAE: Forecasted Estimates (2023-2035)
19.3.4.2. Israel: Forecasted Estimates (2023-2035)
19.3.4.3. Qatar: Forecasted Estimates (2023-2035)
19.3.4.4. Rest of Middle east and North Africa: Forecasted Estimates (2023-2035)
19.3.5. Latin America: Forecasted Estimates (2023-2035)
19.3.5.1. Brazil: Forecasted Estimates (2023-2035)
19.3.5.2. Argentina: Forecasted Estimates (2023-2035)
19.3.5.3. Chile: Forecasted Estimates (2023-2035)
19.3.5.4. Rest of Latin America: Forecasted Estimates (2023-2035)
19.4. Data Triangulation and Validation

20. ONCOLOGY PRECISION MEDICINE MARKET, SALES FORECAST OF DRUGS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Blockbuster Commercialzied Oncology Precision Medicine Market: Sales Forecast
20.3.1. ADCETRIS? Sales Forecast
20.3.2. Alecensa? Sales Forecast
20.3.3. ALUNBRIG? Sales Forecast
20.3.4. Avastin? Sales Forecast
20.3.5. Ayvakit? Sales Forecast
20.3.6. Braftovi?+ Mektovi? Sales Forecast
20.3.7. BRUKINSA? Sales Forecast
20.3.8. CALQUENCE? Sales Forecast
20.3.9. DARZALEX? Sales Forecast
20.3.10. Elunate? Sales Forecast
20.3.11. Empliciti? Sales Forecast
20.3.12. Enhertu? Sales Forecast
20.3.13. IBRANCE? Sales Forecast
20.3.14. ICLUSIG? Sales Forecast
20.3.15. IMBRUVICA? Sales Forecast
20.3.16. IMFINZI? Sales Forecast
20.3.17. INLYTA? Sales Forecast
20.3.18. Keytruda? Sales Forecast
20.3.19. Kadcyla? Sales Forecast
20.3.20. LENVIMA? / KISPLYX? Sales Forecast
20.3.21. Lumakras? / Lumykras? Sales Forecast
20.3.22. Mekinist? Sales Forecast
20.3.23. NERLYNX? Sales Forecast
20.3.24. NINLARO? Sales Forecast
20.3.25. Opdivo? Sales Forecast
20.3.26. Padcev? Sales Forecast
20.3.27. Piqray? Sales Forecast
20.3.28. Sprycel? Sales Forecast
20.3.29. Tabrecta? Sales Forecast
20.3.30. Tagrisso? Sales Forecast
20.3.31. Tasigna? Sales Forecast
20.3.32. Tecentriq? Sales Forecast
20.3.33. VENCLEXTA? Sales Forecast
20.3.34. Verzenio? / Verzenios Sales Forecast
20.3.35. Xospata? Sales Forecast
20.3.36. Xtandi? Sales Forecast
20.3.37. ZEJULA? Sales Forecast
20.4. NDA-filed Oncology Precision Medicine Market: Sales Forecast
20.4.1. Apatinib / Rivoceranib Sales Forecast
20.4.2. Elunate? Sales Forecast

20.5. Phase III Oncology Precision Medicine Market: Sales Forecast
20.5.1. Darovasertib / IDE196 Sales Forecast
20.5.1.1. Darovasertib / IDE196 Regional Sales Forecast
20.5.2. Elenestinib / BLU-263 Sales Forecast
20.5.2.1. Elenestinib / BLU-263 Regional Sales Forecast
20.5.3. Elunate? Sales Forecast
20.5.3.1. Elunate? Sales Forecast by Type of Cancer Targeted
20.5.3.2. Elunate? Regional Sales Forecast
20.5.4. ORPATHYS? Sales Forecast
20.5.4.1. ORPATHYS? Regional Sales Forecast
20.5.5. Pyrotinib Sales Forecast
20.5.5.1. Pyrotinib Sales Forecast by Type of Cancer Targeted
20.5.5.2. Pyrotinib Regional Sales Forecast
20.5.6. SYD985 / (Vic-) trastuzumab duocarmazine) Sales Forecast
20.5.6.1. SYD985 / (Vic-) trastuzumab duocarmazine) Regional Sales Forecast
20.5.7. ZOLINZA? Sales Forecast
20.5.7.1. ZOLINZA? Regional Sales Forecast
21. ONCOLOGY PRECISION MEDICINE MARKET, BY LEADING DRUG DEVELOPERS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Oncology Precision Medicine Market: Distribution by Leading Drug Developers
21.4. Data Triangulation and Validattion
22. CONCLUSION
23. EXECUTIVE INSIGHTS
23.1. Chapter Overview
23.2. Allarity Therapeutics
23.2.1. Company Snapshot
23.2.2. Interview Transcrip
23.3. Elephas
23.3.1. Company Snapshot
23.3.2. Interview Transcript
24. APPENDIX 1: TABULATED DATA
25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS



List of Figures

Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Partnerships and Collaborations
Figure 4.3 Executive Summary: Clinical Trial Analysis
Figure 4.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Evolution of Precision Medicine
Figure 5.2 Oncology Precision Medicine over Traditional Cancer Medicine
Figure 5.3 Steps Involved in Developing Oncology Precision Medicines
Figure 5.4 Challenges Associated with Oncology Precision Medicines
Figure 6.1 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development
Figure 6.2 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Body
Figure 6.3 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Region
Figure 6.4 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Designation
Figure 6.5 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Molecule
Figure 6.6 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Class
Figure 6.7 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Route of Administration
Figure 6.8 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Dosage Regimen
Figure 6.9 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Patient Population
Figure 6.10 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
Figure 6.11 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development and Type of Cancer Targeted
Figure 6.12 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Stage of Development
Figure 6.13 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Molecule
Figure 6.14 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Drug Class
Figure 6.15 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
Figure 6.16 Oncology Precision Medicine: Distribution of Drug Developers by Year of Establishment
Figure 6.17 Oncology Precision Medicine: Distribution of Drug Developers by Company Size
Figure 6.18 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Region)
Figure 6.19 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Country)
Figure 6.20 Oncology Precision Medicine: Distribution of Drug Developers by Company Size and Location of Headquarters (Region)
Figure 6.21 Most Active Developers: Distribution by Number of Oncology Precision Medicines
Figure 7.1 AstraZeneca: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 7.2 Roche (Parent Company of Genentech): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 7.3 Johnson & Johnson (Parent Company of Johnson & Johnson Innovative Medicine): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 7.4 Novartis: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 7.5 Pfizer: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2023
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2018-2023
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Drug Involved
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Cancer Targeted
Figure 9.7 Most Active Players: Distribution by Number of Partnerships
Figure 9.8 Partnership and Collaborations: Local and International Agreements
Figure 9.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 10.1 Clinical Trial Analysis: Cumulative Year-wise Trend, 2018-2023
Figure 10.2 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2018-2023
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2018–2023
Figure 10.6 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.7 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2018–2023
Figure 10.8 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 10.9 Clinical Trial Analysis: Distribution by Patient Gender
Figure 10.10 Clinical Trial Analysis: Distribution by Type of Cancer Targeted
Figure 10.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.12 Clinical Trial Analysis: Distribution by Type of Trial Masking
Figure 10.13 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 10.14 Clinical Trial Analysis: Distribution by Type of Intervention
Figure 10.15 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 10.16 Leading Industry Players: Distribution by Number of Clinical Trials
Figure 10.17 Leading Non-Industry Players: Distribution by Number of Clinical Trials
Figure 10.18 Word Cloud Analysis: Emerging Focus Areas
Figure 10.19 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 10.20 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Figure 10.21 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Figure 11.1 Oncology Precision Medicine Assay Kits: Distribution by Stage of Development
Figure 11.2 Oncology Precision Medicine Assay Kits: Distribution by Regulatory Certification / Compliance
Figure 11.3 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability
Figure 11.4 Oncology Precision Medicine Assay Kits: Distribution by Type of Test
Figure 11.5 Oncology Precision Medicine Assay Kits: Distribution by Type of Sample Used
Figure 11.6 Oncology Precision Medicine Assay Kits: Distribution by Principle of Biomarker Detection
Figure 11.7 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time
Figure 11.8 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted
Figure 11.9 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time and Type of Cancer Targeted
Figure 11.10 Oncology Precision Medicine Assay Kits: Distribution by End-user
Figure 11.11 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability and End-user
Figure 11.12 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted and End-user
Figure 11.13 Oncology Precision Medicine Assay Kit Developers: Distribution by Year of Establishment
Figure 11.14 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size
Figure 11.15 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Region)
Figure 11.16 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Country)
Figure 11.17 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size and Location of Headquarters (Region)
Figure 11.18 Oncology Precision Medicine Assay Kit Developers: Distribution by Business Model
Figure 11.19 Most Active Developers: Distribution by Number of Oncology Precision Medicine Assay Kits Developed
Figure 12.1 Applications of NGS in Oncology Precision Medicine
Figure 12.2 Applications of Nanotechnology in Oncology Precision Medicine
Figure 12.3 Applications of Molecular Imaging Technologies in Oncology Precision Medicine
Figure 12.4 Applications of Omics Technologies in Oncology Precision Medicine
Figure 12.5 Applications of AI in Oncology Precision Medicine
Figure 13.1 Oncology Precision Medicine: Market Drivers
Figure 13.2 Oncology Precision Medicine: Market Restraints
Figure 13.3 Oncology Precision Medicine: Market Opportunities
Figure 13.4 Oncology Precision Medicine: Market Challenges
Figure 14.1 Global Oncology Precision Medicine Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 14.2 Global Oncology Precision Medicine Market, 2023-2035: Conservative Scenario (USD Billion)
Figure 14.3 Global Oncology Precision Medicine Market, 2023-2035: Optimistic Scenario (USD Billion)
Figure 15.1 Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035
Figure 15.2 Oncology Precision Medicine Market for Bladder Cancer, 2023-2035 (USD Billion)
Figure 15.3 Oncology Precision Medicine Market for Blood / Hematologic Cancer, 2023-2035 (USD Billion)
Figure 15.4 Oncology Precision Medicine Market for Breast Cancer, 2023-2035 (USD Billion)
Figure 15.5 Oncology Precision Medicine Market for Cervical Cancer, 2023-2035 (USD Billion)
Figure 15.6 Oncology Precision Medicine Market for Gastrointestinal Cancer, 2023-2035 (USD Billion)
Figure 15.7 Oncology Precision Medicine Market for Head and Neck Squamous Cancer, 2023-2035 (USD Billion)
Figure 15.8 Oncology Precision Medicine Market for Lung Cancer, 2023-2035 (USD Billion)
Figure 15.9 Oncology Precision Medicine Market for Skin Cancer, 2023-2035 (USD Billion)
Figure 15.10 Oncology Precision Medicine Market for Other Cancers, 2023-2035 (USD Billion)
Figure 16.1 Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035
Figure 16.2 Oncology Precision Medicine Market for Oral, 2023-2035 (USD Billion)
Figure 16.3 Oncology Precision Medicine Market for Intravenous, 2023-2035 (USD Billion)
Figure 16.4 Oncology Precision Medicine Market for Others, 2023-2035 (USD Billion)
Figure 17.1 Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035
Figure 17.2 Oncology Precision Medicine Market for Small Molecules, 2023-2035 (USD Billion)
Figure 17.3 Oncology Precision Medicine Market for Biologics, 2023-2035, (USD Billion)
Figure 18.1 Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035
Figure 18.2 Oncology Precision Medicine Market for Kinase Inhibitors, 2023-2035 (USD Billion)
Figure 18.3 Oncology Precision Medicine Market for Enzyme Inhibitors,2023-2035 (USD Billion)
Figure 18.4 Oncology Precision Medicine Market for Immune Checkpoint Inhibitors, 2023-2035 (USD Billion)
Figure 18.5 Oncology Precision Medicine Market for Others, 2023-2035 (USD Billion)
Figure 19.1 Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035
Figure 19.2 Oncology Precision Medicine Market in North America, 2023-2035 (USD Billion)
Figure 19.3 Oncology Precision Medicine Market in the US, 2023-2035 (USD Billion)
Figure 19.4 Oncology Precision Medicine Market in Canada, 2023-2035 (USD Billion)
Figure 19.5 Oncology Precision Medicine Market in Europe, 2023-2035 (USD Billion)
Figure 19.6 Oncology Precision Medicine Market in France, 2023-2035 (USD Billion)
Figure 19.7 Oncology Precision Medicine Market in Germany, 2023-2035 (USD Billion)
Figure 19.8 Oncology Precision Medicine Market in Italy, 2023-2035 (USD Billion)
Figure 19.9 Oncology Precision Medicine Market in Spain, 2023-2035 (USD Billion)
Figure 19.10 Oncology Precision Medicine Market in UK, 2023-2035 (USD Billion)
Figure 19.11 Oncology Precision Medicine Market in Asia, 2023-2035 (USD Billion)
Figure 19.12 Oncology Precision Medicine Market in China, 2023-2035 (USD Billion)
Figure 19.13 Oncology Precision Medicine Market in Japan, 2023-2035 (USD Billion)
Figure 19.14 Oncology Precision Medicine Market in Korea, 2023-2035 (USD Billion)
Figure 19.15 Oncology Precision Medicine Market in India, 2023-2035 (USD Billion)
Figure 19.16 Oncology Precision Medicine Market in Middle East and North Africa, 2023-2035 (USD Billion)
Figure 19.17 Oncology Precision Medicine Market in UAE, 2023-2035 (USD Billion)
Figure 19.18 Oncology Precision Medicine Market in Israel, 2023-2035 (USD Billion)
Figure 19.19 Oncology Precision Medicine Market in Qatar, 2023-2035 (USD Billion)
Figure 19.20 Oncology Precision Medicine Market in Rest of Middle East and North Africa, 2023-2035 (USD Billion)
Figure 19.21 Oncology Precision Medicine Market in Latin America, 2023-2035 (USD Billion)
Figure 19.22 Oncology Precision Medicine Market in Brazil, 2023-2035 (USD Billion)
Figure 19.18 Oncology Precision Medicine Market in Israel, 2023-2035 (USD Billion)
Figure 19.19 Oncology Precision Medicine Market in Chile, 2023-2035 (USD Billion)
Figure 19.20 Oncology Precision Medicine Market in Rest of Latin America, 2023-2035 (USD Billion)
Figure 20.1 Blockbuster Commercialized Oncology Precision Medicine Market: ADCETRIS? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.2 Blockbuster Commercialized Oncology Precision Medicine Market: Alecensa? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.3 Blockbuster Commercialized Oncology Precision Medicine Market: ALUNBRIG? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.4 Blockbuster Commercialized Oncology Precision Medicine Market: Avastin? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.5 Blockbuster Commercialized Oncology Precision Medicine Market: Ayvakit? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.6 Blockbuster Commercialized Oncology Precision Medicine Market: Braftovi?+ Mektovi? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.7 Blockbuster Commercialized Oncology Precision Medicine Market: BRUKINSA? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.8 Blockbuster Commercialized Oncology Precision Medicine Market: CALQUENCE? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.9 Blockbuster Commercialized Oncology Precision Medicine Market: DARZALEX? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.10 Blockbuster Commercialized Oncology Precision Medicine Market: Elunate? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.11 Blockbuster Commercialized Oncology Precision Medicine Market: Empliciti? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.12 Blockbuster Commercialized Oncology Precision Medicine Market: Enhertu? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.13 Blockbuster Commercialized Oncology Precision Medicine Market: IBRANCE? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.14 Blockbuster Commercialized Oncology Precision Medicine Market: ICLUSIG? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.15 Blockbuster Commercialized Oncology Precision Medicine Market: IMBRUVICA? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.16 Blockbuster Commercialized Oncology Precision Medicine Market: IMFINZI? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.17 Blockbuster Commercialized Oncology Precision Medicine Market: INLYTA? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.18 Blockbuster Commercialized Oncology Precision Medicine Market: Keytruda? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.19 Blockbuster Commercialized Oncology Precision Medicine Market: Kadcyla? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.20 Blockbuster Commercialized Oncology Precision Medicine Market: LENVIMA? / KISPLYX? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.21 Blockbuster Commercialized Oncology Precision Medicine Market: Lumakras? / Lumykras? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.22 Blockbuster Commercialized Oncology Precision Medicine Market: Mekinist? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.23 Blockbuster Commercialized Oncology Precision Medicine Market: NERLYNX? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.24 Blockbuster Commercialized Oncology Precision Medicine Market: NINLARO? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.25 Blockbuster Commercialized Oncology Precision Medicine Market: Opdivo? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.26 Blockbuster Commercialized Oncology Precision Medicine Market: Padcev? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.27 Blockbuster Commercialized Oncology Precision Medicine Market: Piqray? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.28 Blockbuster Commercialized Oncology Precision Medicine Market: Sprycel? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.29 Blockbuster Commercialized Oncology Precision Medicine Market: Tabrecta? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.30 Blockbuster Commercialized Oncology Precision Medicine Market: Tagrisso? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.31 Blockbuster Commercialized Oncology Precision Medicine Market: Tasigna? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.32 Blockbuster Commercialized Oncology Precision Medicine Market: Tecentriq? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.33 Blockbuster Commercialized Oncology Precision Medicine Market: VENCLEXTA? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.34 Blockbuster Commercialized Oncology Precision Medicine Market: Verzenio? / Verzenios Sales Forecast, 2023-2035 (USD Billion)
Figure 20.35 Blockbuster Commercialized Oncology Precision Medicine Market: Xospata? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.36 Blockbuster Commercialized Oncology Precision Medicine Market: XTANDI? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.37 Blockbuster Commercialized Oncology Precision Medicine Market: ZEJULA? Sales Forecast, 2023-2035 (USD Billion)
Figure 20.38 NDA-filed Oncology Precision Medicine Market: Apatinib / Rivoceranib Sales Forecast, 2024-2035 (USD Billion)
Figure 20.39 NDA-filed Oncology Precision Medicine Market: Elunate? Sales Forecast, 2025-2035 (USD Billion)
Figure 20.40 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Sales Forecast, 2030-2035 (USD Billion)
Figure 20.41 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Regional Sales Forecast, 2030-2035 (USD Billion)
Figure 20.42 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Sales Forecast, 2030-2035 (USD Billion)
Figure 20.43 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Regional Sales Forecast, 2030-2035 (USD Billion)
Figure 20.44 Phase III Oncology Precision Medicine Market: Elunate? Sales Forecast, 2025-2035 (USD Billion)
Figure 20.45 Phase III Oncology Precision Medicine Market: Elunate? Sales Forecast by Type of Cancer Targeted, 2025-2035 (USD Billion)
Figure 20.46 Phase III Oncology Precision Medicine Market: Elunate? Regional Sales Forecast, 2025-2035 (USD Billion)
Figure 20.47 Phase III Oncology Precision Medicine Market: ORPATHYS? Sales Forecast, 2028-2035 (USD Billion)
Figure 20.48 Phase III Oncology Precision Medicine Market: ORPATHYS? Regional Sales Forecast, 2028-2035 (USD Billion)
Figure 20.49 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast, 2025-2035 (USD Billion)
Figure 20.50 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast by Type of Cancer Targeted, 2025-2035 (USD Billion)
Figure 20.51 Phase III Oncology Precision Medicine Market: Pyrotinib Regional Sales Forecast, 2025-2035 (USD Billion)
Figure 20.52 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-)trastuzumab duocarmazine) Sales Forecast, 2025-2035 (USD Billion)
Figure 20.53 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-)trastuzumab duocarmazine) Regional Sales Forecast, 2025-2035 (USD Billion)
Figure 20.54 Phase III Oncology Precision Medicine Market: ZOLINZA? Sales Forecast, 2024-2035 (USD Billion)
Figure 20.55 Phase III Oncology Precision Medicine Market: ZOLINZA? Regional Sales Forecast, 2024-2035 (USD Billion)
Figure 21.1 Oncology Precision Medicine Market: Distribution by Leading Drug Developers (based on sales of oncology precision medicines in the year 2022 (USD Billion))
Figure 22.1 Conclusion: Market Landscape
Figure 22.2 Conclusion: Partnerships and Collaborations
Figure 22.3 Conclusion: Clinical Trial Analysis
Figure 22.4 Conclusion: Case Study Oncology Precision Medicine Assay Kits
Figure 22.5 Conclusion: Market Forecast and Opportunity Analysis

List of Tables

Table 6.1 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Developer, Brand, Stage of Development, Approval Body and Approval Region
Table 6.2 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Drug Designation
Table 6.3 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Type of Molecule, Drug Class, Route of Administration, Dosage Regimen and Patient Population
Table 6.4 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Type of Cancer Targeted
Table 6.5 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Developer and Stage of Development
Table 6.6 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Type of Molecule and Drug Class
Table 6.7 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Type of Cancer Targeted
Table 6.8 Oncology Precision Medicine: List of Developers
Table 7.1 Oncology Precision Medicine: List of Companies Profiled
Table 7.2 AstraZeneca: Company Snapshot
Table 7.3 AstraZeneca: Oncology Precision Medicine Portfolio
Table 7.4 AstraZeneca: Recent Developments and Future Outlook
Table 7.5 Genentech: Company Snapshot
Table 7.6 Genentech: Oncology Precision Medicine Portfolio
Table 7.7 Jiangsu Hengrui Pharmaceuticals: Company Snapshot
Table 7.8 Jiangsu Hengrui Pharmaceuticals: Oncology Precision Medicine Portfolio
Table 7.9 Johnson & Johnson Innovative Medicine: Company Snapshot
Table 7.10 Johnson & Johnson Innovative Medicine: Oncology Precision Medicine Portfolio
Table 7.11 Johnson & Johnson Innovative Medicine: Recent Developments and Future Outlook
Table 7.12 Novartis: Company Snapshot
Table 7.13 Novartis: Oncology Precision Medicine Portfolio
Table 7.14 Novartis: Recent Developments and Future Outlook
Table 7.15 Pfizer: Company Snapshot
Table 7.16 Pfizer: Oncology Precision Medicine Portfolio
Table 7.17 Pfizer: Recent Developments and Future Outlook
Table 7.18 SpringWorks Therapeutics: Company Snapshot
Table 7.19 SpringWorks Therapeutics: Oncology Precision Medicine Portfolio
Table 7.20 SpringWorks Therapeutics: Recent Developments and Future Outlook
Table 8.1 Oncology Precision Medicine: List of Companies Profiled
Table 8.2 Company Profile: AbbVie
Table 8.3 Company Profile: Anticancer Biosciences
Table 8.4 Company Profile: Astellas Pharma
Table 8.5 Company Profile: Bayer
Table 8.6 Company Profile: Blueprint Medicines
Table 8.7 Company Profile: Bristol Myers Squibb
Table 8.8 Company Profile: Eli Lilly
Table 8.9 Company Profile: Erasca
Table 8.10 Company Profile: GlaxoSmithKline
Table 8.11 Company Profile: Hutchmed
Table 8.12 Company Profile: IDEAYA Biosciences
Table 8.13 Company Profile: Merck
Table 8.14 Company Profile: Repare Therapeutics
Table 8.15 Company Profile: Roche
Table 8.16 Company Profile: Seagen
Table 8.17 Company Profile: Takeda Pharmaceutical
Table 8.18 Company Profile: VERAXA Biotech GmbH
Table 8.19 Company Profile: VRise Therapeutics
Table 9.1 Oncology Precision Medicine: List of Partnerships and Collaborations, 2018-2023
Table 9.2 Partnerships and Collaborations: Information on Drug Involved and Type of Cancer Targeted
Table 9.3 Partnerships and Collaborations: Information on Location of Headquarters (Country and Region) and Type of Agreement (Country and Region)
Table 11.1 Oncology Precision Medicine Assay Kits: Information on Developer, Stage of Development, Regulatory Certification / Compliance and Regional Availability
Table 11.2 Oncology Precision Medicine Assay Kits: Information on Type of Test, Type of Sample, Principle of Biomarker Detection and Turn-around Time
Table 11.3 Oncology Precision Medicine Assay Kits: Information on Type of Cancer Targeted
Table 11.4 Oncology Precision Medicine Assay Kits: Information on End-user
Table 11.5 List of Oncology Precision Medicine Assay Kit Developers
Table 21.1 List of Leading Oncology Precision Medicine Developers
Table 23.1 Allarity Therapeutics: Company Snapshot
Table 23.2 Elephas: Company Snapshot
Table 24.1 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development
Table 24.2 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Body
Table 24.3 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Region
Table 24.4 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Designation
Table 24.5 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Molecule
Table 24.6 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Class
Table 24.7 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Route of Administration
Table 24.8 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Dosage Regimen
Table 24.9 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Patient Population
Table 24.10 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
Table 24.11 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development and Type of Cancer Targeted
Table 24.12 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Stage of Development
Table 24.13 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Molecule
Table 24.14 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Drug Class
Table 24.15 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
Table 24.16 Oncology Precision Medicine: Distribution of Drug Developers by Year of Establishment
Table 24.17 Oncology Precision Medicine: Distribution of Drug Developers by Company Size
Table 24.18 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Region)
Table 24.19 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Country)
Table 24.20 Oncology Precision Medicine: Distribution of Drug Developers by Company Size and Location of Headquarters (Region)
Table 24.21 Most Active Developers: Distribution by Number of Oncology Precision Medicines
Table 24.22 AstraZeneca: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 24.23 Roche (Parent Company of Genentech): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 24.24 Johnson & Johnson (Parent Company of Johnson & Johnson Innovative Medicine): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 24.25 Novartis: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 24.26 Pfizer: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 24.27 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2023
Table 24.28 Partnerships and Collaborations: Distribution by Type of Partnership
Table 24.29 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2018-2023
Table 24.30 Partnerships and Collaborations: Distribution by Type of Partner
Table 24.31 Partnerships and Collaborations: Distribution by Drug Involved
Table 24.32 Partnerships and Collaborations: Distribution by Type of Cancer Targeted
Table 24.33 Most Active Players: Distribution by Number of Partnerships
Table 24.34 Partnership and Collaborations: Local and International Agreements
Table 24.35 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 24.36 Clinical Trial Analysis: Cumulative Year-wise Trend, 2018-2023
Table 24.37 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2018-2023
Table 24.38 Clinical Trial Analysis: Distribution by Trial Phase
Table 24.39 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Table 24.40 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2018–2023
Table 24.41 Clinical Trial Analysis: Distribution by Trial Status
Table 24.42 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2018–2023
Table 24.43 Clinical Trial Analysis: Distribution by Target Patient Population
Table 24.44 Clinical Trial Analysis: Distribution by Patient Gender
Table 24.45 Clinical Trial Analysis: Distribution by Type of Cancer Targeted
Table 24.46 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 24.47 Clinical Trial Analysis: Distribution by Type of Trial Masking
Table 24.48 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 24.49 Clinical Trial Analysis: Distribution by Type of Intervention
Table 24.50 Clinical Trial Analysis: Distribution by Trial Purpose
Table 24.51 Leading Industry Players: Distribution by Number of Clinical Trials
Table 24.52 Leading Non-Industry Players: Distribution by Number of Clinical Trials
Table 24.53 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 24.54 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Table 24.55 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Table 24.56 Oncology Precision Medicine Assay Kits: Distribution by Stage of Development
Table 24.57 Oncology Precision Medicine Assay Kits: Distribution by Regulatory Certification / Compliance
Table 24.58 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability
Table 24.59 Oncology Precision Medicine Assay Kits: Distribution by Type of Test
Table 24.60 Oncology Precision Medicine Assay Kits: Distribution by Type of Sample Used
Table 24.61 Oncology Precision Medicine Assay Kits: Distribution by Principle of Biomarker Detection
Table 24.62 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time
Table 24.63 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted
Table 24.64 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time and Type of Cancer Targeted
Table 24.65 Oncology Precision Medicine Assay Kits: Distribution by End-user
Table 24.66 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability and End-user
Table 24.67 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted and End-user
Table 24.68 Oncology Precision Medicine Assay Kit Developers: Distribution by Year of Establishment
Table 24.69 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size
Table 24.70 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Region)
Table 24.71 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Country)
Table 24.72 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size and Location of Headquarters (Region)
Table 24.73 Oncology Precision Medicine Assay Kit Developers: Distribution by Business Model
Table 24.74 Most Active Developers: Distribution by Number of Oncology Precision Medicine Assay Kits Developed
Table 24.75 Global Oncology Precision Medicine Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 24.76 Global Oncology Precision Medicine Marke